2curex Ab · OMXSTO:2CUREX
2curex Ab — Investor Presentation (November 2020)
15 slides from 2curex Ab's investor presentation, November 2020
Slide 1: Because patients are individuals
Because patients are individuals
Slide 2: Agenda: key messages, 2cureX in brief, IndiTreat test
Ole Thastrup • Key messages CEO • 2cureX in brief • The IndiTreat® test • Clinical validation and pipeline • Commercial roadmap Maarten van der Linden • Why invest in 2cureX CBO Because patients are individuals
Slide 3: Key messages
• 2cureX is meeting a tremendous medical need • 2cureX has introduced the world’s first CE-marked and ISO13485 compliant Microtumor test (IndiTreat) • IndiTreat® commercially launched at ESMO (October 2020) • 2cureX has a strong clinical pipeline in major cancers • 2cureX has a strong financial posi
Slide 4: 2cureX spun-out from Carlsberg Research Center
2007 2015 2017 2018-2019 2018-2020 2020 2020 - 2cureX spun-out 2cureX GmbH Clinical trial in Management team 2nd family of Last patient enrolled in Commercialization from Carlsberg established in Colorectal expanded with CBO, patents issued Colorectal Cancer trial Research Center Hamburg Cancer init
Slide 5: … because cancer patients are individuals
”… because cancer patients are individuals" - because cancer patients are individuals
Slide 6: Because cancer patients are individuals
- because cancer patients are individuals
Slide 7: Ineffective vs effective medical treatment
®- Ineffective medical Effective medical treatment treatment selected by IndiTreat® - because cancer patients are individuals
Slide 8: Because cancer patients are individuals
- because cancer patients are individuals
Slide 9: Patient-derived microtumors
Patient-derived micrtumors • • • - because cancer patients are individuals
Slide 10: Colorectal cancer clinical trial
Last patient enrolled (Oct 2020) Principal Investigator: Lars Henrik Jensen; Chief Oncologist University Hospital Vejle Patient data will be assembled and analysed end of 2020 Interim analysis in Febr. 2019: The trial will answer three essential questions: • Can a microtumor functional test be condu
Slide 11: Total available market for IndiTreat testing in Europe
Total available market for IndiTreat® testing in Europe Colorectal cancer 700.000 new Ovarian cancer cases per year Pancreatic cancer in Europe - because cancer patients are individuals - because cancer patients are individuals
Slide 12: Product focus, market focus and target customers 2021-2023
2021 2022 2023 Product Focus Colorectal Colorectal, Ovarian , Pancreatic 4 – 5 Indications Market Focus Nordics EU markets + UK EU markets + UK + Selected Asian markets Target Customers Key cancer centers Larger Regional Hospitals General Hospitals Sales Own sales reps (n=5) Own sales organization (
Slide 13: Clinical trials and partners
Group 5 Group 1 Group 3 Patient Clinical trials Patient societies stratification Partners partners Group 4 Group 2 Commercial Academic + Partners / Sales Technical Partners Channels - because cancer patients are individuals
Slide 14: Quote from Chief Medical Officer
“I am convinced that IndiTreat® is the missing piece of the cancer treatment Henrik Harling puzzle” Chief Medical Officer, 2cureX - because cancer patients are individuals
Slide 15: Thank you for your attention
Follow us by signing up for News on www.2curex.com and on: • There is a tremendous medical need for making cancer treatment more effective – 2cureX has the “puzzle piece” for making this possible • 2cureX has introduced the world’s first CE-marked and ISO13485 compliant Microtumor test (IndiTreat®)